




 Cite this: *RSC Adv.*, 2024, 14, 9440

 Received 12th January 2024
 Accepted 5th March 2024

DOI: 10.1039/d4ra00320a

rsc.li/rsc-advances

Copper-catalyzed synthesis of primary amides through reductive N–O cleavage of dioxazolones†


 Hyeonwoong Bae,^{ab} Jinhwan Park,^{ab} Rahyun Yoon,^b Seunghoon Lee ^{*ab} and Jongwoo Son ^{*ab}

A new method for the synthesis of primary amides is developed, in which dioxazolones are treated with a copper catalyst under mild reaction conditions. A broad scope of dioxazolones is exhibited as well as dioxazolones containing biologically active structural motifs. These robust and mild reaction conditions allow the transformation of dioxazolones to primary amides, in which sensitive functional groups such as hydroxyl, aldehyde, trialkylsilyl, and unsaturated carbon units are tolerated with excellent chemoselectivity.


Amides are among the most invaluable functional groups in organic chemistry and have been extensively utilized in drug discovery, functional materials, and natural products.^{1–5} In particular, primary amides and carbonyl groups directly bearing a free-NH₂ unit, can serve as key synthetic intermediates in a wide range of *N*-substituted amides through catalytic C–N bond formation using transition metals such as copper and palladium.^{6–8} Several conventional strategies for the preparation of primary amides rely on the use of readily available carboxylic acid sources, ammonia treatment, activating agents such as thionyl chloride and oxalyl chloride, peptide-coupling agents, and phosphine-fluoride reagent system (Scheme 1A).^{9–15} Moreover, catalytic hydration of organic nitriles has been explored to avoid undesired hydrolysis to carboxylic acids using transition metal catalysts such as cobalt, ruthenium, palladium, rhodium, and platinum.^{16–18} However, these approaches are challenging because of their low functional group tolerance under harsh reaction conditions and reduced sustainability, which can produce toxic chemicals that may negatively impact environmental systems.¹⁹ Instead of carboxylic acids, hydroxamic acids and their derivatives are widely used to access primary amides (Scheme 1B). Several synthetic approaches have been developed from Weinreb amides to access primary amides, facilitated through weak N–O bond cleavage (55–65 kcal mol^{−1}) using stoichiometric amounts of metal-based reducing agents such as Mo(CO)₆,^{20–22} TiCl₃,^{23–25} SmI₂,^{26,27} Zn,^{28,29} and Li/NH₃(l).^{30,31} Moreover, catalytic hydrogenation by the Raney-Ni³² and Pd/C³³ protocols can further reduce other functional groups, such as carbonyls and unsaturated carbon motifs. More recently,

organic photocatalytic systems have proven effective in cleaving N–O bonds through a single-electron transfer process, avoiding the use of stoichiometric reductants under mild conditions.³⁴ In addition, *O*-acylated hydroxamic acids bearing weak N–O bonds


A) Conventional amide syntheses




B) Reductive N–O bond cleavage of hydroxamic acid and their analogues



C) Copper-catalyzed(or -mediated) decarboxylative reductive transformations



D) This work: Copper-catalyzed synthesis of primary amides from dioxazolones



^aDepartment of Chemical Engineering (BK21 FOUR Graduate Program), Dong-A University, 37 Nakdong-Daero 550beon-gil, Saha-gu, Busan 49315, South Korea. E-mail: sonorganic@dau.ac.kr

^bDepartment of Chemistry, Dong-A University, 37 Nakdong-Daero 550beon-gil, Saha-gu, Busan 49315, South Korea

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra00320a>

Scheme 1 Synthetic methodology for primary amides.




(45 kcal mol⁻¹) were effectively converted to primary amides by copper(II) salts³⁵ and ruthenium catalysts.³⁶ Moreover, a recent study showcased hydroxamic acids as amide sources, easily synthesized from carboxylic acids and hydroxylamine using 1,1'-carbonyldiimidazole, would be reduced to corresponding primary amides using thioacetic acid, NH₄HCO₃ in ethanol.³⁷ In the past decade, dioxazolones, first invented by Beck and coworkers,³⁸ have been widely studied in the research area of catalytic C–H amidations using precious transition metals such as iridium and rhodium.^{39–48} Despite the development of dioxazolones in transition metal catalysis, an alternative catalytic system is recognized to set the stage for a more convenient reaction regime that can be utilized under milder reaction conditions. Copper, one of the 3d transition metals, getting more attentions owing to its cost-effectiveness, low toxicity, and earth abundance.⁴⁹ Recently, several decarboxylative *N*-functionalizations of dioxazolones using copper salts have been reported (Scheme 1C). First, the research group of de Bruin reported a preparation of *N*-acyl amidines from three-component reaction of dioxazolones, terminal alkynes, and amines using copper(I) catalyst.⁵⁰ In addition, the enantioselective hydroamidation of styrene motifs was studied using a copper-hydride catalytic system.⁵¹ More recently, decarboxylative *N*-arylation of dioxazolones using boronic acids has been reported.⁵² All these transformations of dioxazolones using copper salts have been proposed to engage the formation of copper(III) species from terminal alkynes, alkenes, and arylboronic acids.

Based on these previously reported transformations of dioxazolones, we anticipated that if we use silane as a hydrogen source, the reaction might undergo N–O bond cleavage, resulting in the formation of primary amides (Scheme 1D). Herein, we report the first example of the synthesis of primary amides using dioxazolones as a convenient methodology to access a variety of primary amides.

We began the optimization screening using dioxazolone **1a** as the starting material (Table 1). Optimization screening was commenced using γ -valerolactone (GVL) as a biomass-derived green solvent.⁵³ Initial investigations using several copper salts indicated that the reaction with copper(II) acetate afforded the best performance (entry 1–3). Ligand screening showed that nitrogen-based ligands outweighed phosphine-based ligands, resulting in 1,10-phenanthroline being the best ligand system (entry 4–6). Further solvent screening revealed that GVL was the optimal solvent (entry 7–11). Several reductive N–O bond cleavage of isoxazolines and 2-oxa-3-azabicyclic compounds have been studied using copper(0) nanoparticle and heterogeneous copper-on-carbon in the absence of silane.^{54,55} It is noteworthy that the reaction without silane gave trace amount of amide, indicating the use of silane is essential (entry 9). To confirm that the reaction was not possible, several control experiments were further performed, which indicated that the copper catalyst was pivotal (entry 12 and 13). Based on these results, optimal reaction parameters were determined, demonstrating a catalytic copper(II) system using GVL as an environmentally benign solvent. Further screening of several N–O bond-containing scaffolds was explored under standard

Table 1 Optimization of the synthesis of primary amides from dioxazolones^a



Entry	[Cu]	Ligand	Solvent	Yield (%)
1	CuCl	1,10-Phen	GVL	41
2	Cu(OAc) ₁	1,10-Phen	GVL	92
3	Cu(OAc) ₂	1,10-Phen	GVL	98
4	Cu(OAc) ₂	DPPE	GVL	<5
5	Cu(OAc) ₂	PPh ₃	GVL	<5 ^b
6	Cu(OAc) ₂	Pyridine	GVL	95 ^b
7	Cu(OAc) ₂	1,10-Phen	DMF	45
8	Cu(OAc) ₂	1,10-Phen	DCE	95
9	Cu(OAc) ₂	1,10-Phen	DCE	<5 ^c
10	Cu(OAc) ₂	1,10-Phen	MeOH	50
11	Cu(OAc) ₂	1,10-Phen	Benzene	57
12	—	1,10-Phen	GVL	N.R
13	Cu(OAc) ₂	—	GVL	26


^a Reaction conditions: **1a** (0.2 mmol), Cu(OAc)₂ (2 mol%), 1,10-phenanthroline (2 mol%), Ph₂SiH₂ (2.0 equiv.), and solvent (1 mL) under argon at room temperature for 18 h. ^b Ligand (4 mol%) was used. ^c Without Ph₂SiH₂.

reaction conditions, revealing dioxazolone **1a** was the optimal amide precursor in this transformation (see the ESI†).


Under the optimized reaction conditions, the substrate scope of the dioxazolones was assessed to probe their reactivity, as shown in Scheme 2. Phenyl dioxazolones bearing methoxy, hydrogen, and *tert*-butyl substituents were transformed into the corresponding primary amides **2a–2d** in excellent yields. Regioisomeric tolyl-dioxazolones were also successful, suggesting that the transformation was affected by steric factors (**2e–2g**). Dioxazolones bearing halogens were shown to be effective, affording the targeted primary amides **2h–2k** in good to excellent yields. Notably, dioxazolones with electron-poor substituents, such as trifluoromethyl, nitrile, and nitro groups, were smoothly converted to the desired primary amides **2l–2n**. Based on these results, the reduction system could be applied to both electron-rich and electron-poor dioxazolones. Fused and heteroaromatic motifs were also tolerated in this transformation (**2o–2r**). Excellent yields were obtained for dioxazolones containing aliphatic alkyl motifs (**2s–2u**). In addition, the trialkylsilyl protecting group remained intact in this transformation (**2v**). Surprisingly, the free OH-containing dioxazolone successfully underwent targeted reduction in high yield (**2w**). Notably, our catalytic reduction system represents a good chemoselective reduction process for the N–O bond of dioxazolone motifs rather than those of other possible unsaturated functional groups, such as aldehyde and alkene motifs (**2x** and **2y**).

Motivated by this example of dioxazolone **1**, we expanded our attention to dioxazolones bearing bioactive structural motifs (Scheme 3). Several dioxazolones derived from naturally





Scheme 2 Scope of dioxazolones 1. ^a 4 mol% of $\text{Cu}(\text{OAc})_2$ and 4 mol% of 1,10-phenanthroline are used.



Scheme 3 Scope of bioactive motif-containing dioxazolones 3. ^a 4 mol% of $\text{Cu}(\text{OAc})_2$ and 4 mol% of 1,10-phenanthroline are used.


occurring compounds such as glycine, citronellic acid, lauric acid, and cinnamic acid have been tested under standard reaction conditions and have shown promising reactivities (4a–

4d). Moreover, dioxazolones bearing bioactive structural motifs, such as felbinac and probenecid, which are commercially available drugs, have been shown to be applicable to the corresponding primary amides (4e–4f). The poor yields of 4a and 4e were observed owing to the low conversion of dioxazolones. Based on these results, we anticipate that our reduction protocol for dioxazolones is more efficient for accessing primary amides, owing to the mild reaction conditions and convenient reaction setup.


We also extended our reduction protocol to a large-scale process (Scheme 4). Several aryl- and aliphatic-substituted dioxazolones afforded the corresponding primary amides (2a, 2s, and 4c) in excellent yields. Based on these trials, it is anticipated that the catalytic reductive transformation of dioxazolones is amenable to large-scale processes (20 mmol scale of dioxazolones), highlighting the operationally simple procedure and mild reaction conditions without any significant loss of product formation.

The robustness of the transformation was represented by practical copper catalysis in the presence of water (Scheme 5). We were excited to observe that the reaction was still amenable when 10 equivalent of water was present in reaction medium, implying the desired transformation was potentially nontoxic with excellent tolerance. It is noteworthy that the presence of 100 equivalent of water showed diminished reactivity presumably owing to lower solubility.

To provide mechanistic insight into this transformation, several mechanistic studies were explored (Scheme 6). Stryker's reagent, a phosphine-based mild copper hydride source, resulted in no conversion of 1a (Scheme 6a). Interestingly, the same process with 1,10-phenanthroline ligand showed a promising reactivity, implying the use of nitrogen-based ligand is crucial in this transformation. In addition, a radical trapping experiment was performed using TEMPO (Scheme 6b). The addition of TEMPO to the reaction mixture for 10 min inhibited the reduction process. Moreover, the formation of silyl formate was not observed, implying the catalytic reduction of carbon dioxide




Scheme 4 Gram-scale synthesis of primary amides 2 and 4.




Scheme 5 Catalytic performance in the presence of H_2O .





Scheme 6 Mechanistic studies.



Scheme 7 Proposed reaction pathway.

byproduct was not possible in this transformation (see the ESI^+).^{56–58} Based on this experiment, a radical-involving mechanism was envisioned.

Based on mechanistic observations and previous studies, a plausible reaction pathway was proposed (Scheme 7). The reaction commences with the association of dioxazolone **1** onto the copper catalyst to afford the complex **A**. Incorporation of silane as a reductant furnished decarboxylated amide–copper complex **B**, followed by hydrogen atom abstraction and protonation to afford a desired primary amide **2**, which is supported by the experiment with radical trapping experiment. However, we cannot completely rule out the pathway based on the formation of copper hydride involving oxidative N–O bond insertion of dioxazolone, decarboxylative reductive elimination, and protonation processes.^{59,60}

Conclusions

In summary, we have investigated the Cu-catalyzed preparation of primary amides from dioxazolones using silanes. γ -

valerolactone as a solvent was used in this transformation, featuring more sustainable reaction condition for primary amides. The scope of dioxazolones in this transformation was well tolerated with excellent chemoselectivity. In addition, we developed a sustainable copper catalytic system and synthesized several dioxazolones bearing biologically active structural motifs, highlighting a convenient synthetic approach to potentially bioactive primary amide analogs. The gram-scale test also demonstrated the possible large-scale production of primary amides in a more sustainable manner under mild reaction conditions. Further detailed mechanistic studies are underway in our laboratory to delineate the nature of catalytic reduction process.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by a National Research Foundation of Korea grant (NRF-2021R1F1A1062822) funded by the South Korean government (MSIT). This work was also supported by the Korea Environment Industry & Technology Institute (KEITI) through the Technology Development Program for Safety Management of Household Chemical Products, funded by the Korea Ministry of Environment (MOE) (202200298).

References

- X. Guo, A. Facchetti and T. J. Marks, *Chem. Rev.*, 2014, **114**, 8943–9021.
- D.-W. Zhang, X. Zhao, J.-L. Hou and Z.-T. Li, *Chem. Rev.*, 2012, **112**, 5271–5316.
- B. L. Bray, *Nat. Rev. Drug Discovery*, 2003, **2**, 587–593.
- A. K. Ghose, V. N. Viswanadhan and J. J. Wendoloski, *J. Comb. Chem.*, 1999, **1**, 55–68.
- J. M. Humphrey and A. R. Chamberlin, *Chem. Rev.*, 1997, **97**, 2243–2266.
- P. Ruiz-Castillo and S. L. Buchwald, *Chem. Rev.*, 2016, **116**, 12564–12649.
- A. Klapars, X. Huang and S. L. Buchwald, *J. Am. Chem. Soc.*, 2002, **124**, 7421–7428.
- A. Klapars, J. C. Antilla, X. Huang and S. L. Buchwald, *J. Am. Chem. Soc.*, 2001, **123**, 7727–7729.
- V. R. Pattabiraman and J. W. Bode, *Nature*, 2011, **480**, 471–479.
- A. El-Faham and F. Albericio, *Chem. Rev.*, 2011, **111**, 6557–6602.
- E. Valeur and M. Bradley, *Chem. Soc. Rev.*, 2009, **38**, 606–631.
- S.-Y. Han and Y.-A. Kim, *Tetrahedron*, 2004, **60**, 2447–2467.
- M. Tryniszewski and M. Barbasiewicz, *Synthesis*, 2021, **54**, 1446–1460.
- S. B. Munoz, H. Dang, X. Ispizua-Rodriguez, T. Mathew and G. K. S. Prakash, *Org. Lett.*, 2019, **21**, 1659–1663.
- R. P. Singh and T. Umamoto, *J. Org. Chem.*, 2011, **76**, 3113–3121.



- 16 Y. Xia, D. He and W. Wu, *Chin. J. Org. Chem.*, 2021, **41**, 969–982.
- 17 R. García-Álvarez, J. Francos, E. Tomás-Mendivil, P. Crochet and V. Cadierno, *J. Organomet. Chem.*, 2014, **771**, 93–104.
- 18 T. J. Ahmed, S. M. M. Knapp and D. R. Tyler, *Coord. Chem. Rev.*, 2011, **255**, 949–974.
- 19 A. Isidro-Llobet, M. N. Kenworthy, S. Mukherjee, M. E. Kopach, K. Wegner, F. Gallou, A. G. Smith and F. Roschangar, *J. Org. Chem.*, 2019, **84**, 4615–4628.
- 20 A. R. Ritter and M. J. Miller, *J. Org. Chem.*, 1994, **59**, 4602–4611.
- 21 S. Cicchi, A. Goti, A. Brandi, A. Guarna and F. De Sarlo, *Tetrahedron Lett.*, 1990, **31**, 3351–3354.
- 22 M. Nitta and T. Kobayashi, *J. Chem. Soc., Perkin Trans. 1*, 1985, 1401–1406.
- 23 L. E. Fisher, J. M. Caroon, Jahangir, S. R. Stabler, S. Lundberg and J. M. Muchowski, *J. Org. Chem.*, 1993, **58**, 3643–3647.
- 24 P. G. Mattingly and M. J. Miller, *J. Org. Chem.*, 1980, **45**, 410–415.
- 25 G. H. Timms and E. Wildsmith, *Tetrahedron Lett.*, 1971, **12**, 195–198.
- 26 G. E. Keck, T. T. Wager and S. F. McHardy, *Tetrahedron*, 1999, **55**, 11755–11772.
- 27 G. E. Keck, S. F. McHardy and T. T. Wager, *Tetrahedron Lett.*, 1995, **36**, 7419–7422.
- 28 G. Kresze and G. Schulz, *Tetrahedron*, 1961, **12**, 7–12.
- 29 Y. A. Arbuzov, *Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1952, **1**, 607–611.
- 30 C. Taillier, V. Bellosta, C. Meyer and J. Cossy, *Org. Lett.*, 2004, **6**, 2145–2147.
- 31 M. Yus, G. Radivoy and F. Alonso, *Synthesis*, 2001, **2001**, 0914–0918.
- 32 D. Klamann, P. Weyerstahl, M. Fligge and K. Ulm, *Chem. Ber.*, 1966, **99**, 561–565.
- 33 S. D'Andrea, Z. B. Zheng, K. DenBleyker, J. C. Fung-Tomec, H. Yang, J. Clark, D. Taylor and J. Bronson, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 2834–2839.
- 34 J. Soika, C. McLaughlin, T. Nevesely, C. G. Daniliuc, J. J. Molloy and R. Gilmour, *ACS Catal.*, 2022, **12**, 10047–10056.
- 35 S. P. Wathen and A. W. Czarnik, *Bioorg. Med. Chem. Lett.*, 1993, **3**, 1245–1246.
- 36 T. You, M. Zhang, J. Chen, H. Liu and Y. Xia, *Org. Chem. Front.*, 2021, **8**, 112–119.
- 37 R. Wang, Y. Chen, B. Fei, J. Hu, J. Chen, Y. Luo and Y. Xia, *Org. Lett.*, 2023, **25**, 2970–2974.
- 38 G. Beck, *Chem. Ber.*, 1951, **84**, 688–689.
- 39 M. Lee, J. Heo, D. Kim and S. Chang, *J. Am. Chem. Soc.*, 2022, **144**, 3667–3675.
- 40 S. Y. Hong, Y. Hwang, M. Lee and S. Chang, *Acc. Chem. Res.*, 2021, **54**, 2683–2700.
- 41 K. M. van Vliet and B. de Bruin, *ACS Catal.*, 2020, **10**, 4751–4769.
- 42 S. Y. Hong, Y. Park, Y. Hwang, Y. B. Kim, M.-H. Baik and S. Chang, *Science*, 2018, **359**, 1016–1021.
- 43 S. Y. Hong, D. Kim and S. Chang, *Nat. Catal.*, 2021, **4**, 79–88.
- 44 J. Park, J. Lee and S. Chang, *Angew. Chem., Int. Ed.*, 2017, **56**, 4256–4260.
- 45 Y. Hwang, Y. Park and S. Chang, *Chem.–Eur. J.*, 2017, **23**, 11147–11152.
- 46 Y. Park, S. Jee, J. G. Kim and S. Chang, *Org. Process Res. Dev.*, 2015, **19**, 1024–1029.
- 47 J. Park and S. Chang, *Angew. Chem., Int. Ed.*, 2015, **54**, 14103–14107.
- 48 V. Bizet, L. Buglioni and C. Bolm, *Angew. Chem., Int. Ed.*, 2014, **53**, 5639–5642.
- 49 P. Gandeepan, T. Müller, D. Zell, G. Cera, S. Warratz and L. Ackermann, *Chem. Rev.*, 2019, **119**, 2192–2452.
- 50 K. M. van Vliet, L. H. Polak, M. A. Siegler, J. I. van der Vlugt, C. F. Guerra and B. de Bruin, *J. Am. Chem. Soc.*, 2019, **141**, 15240–15249.
- 51 Y. Zhou, O. D. Engl, J. S. Bandar, E. D. Chant and S. L. Buchwald, *Angew. Chem., Int. Ed.*, 2018, **57**, 6672–6675.
- 52 A. K. Adegboyega and J. Son, *Org. Lett.*, 2022, **24**, 4925–4929.
- 53 D. M. Alonso, S. G. Wettstein and J. A. Dumesic, *Green Chem.*, 2013, **15**, 584–595.
- 54 K. S. Gayen, T. Sengupta, Y. Saima, A. Das, D. K. Maiti and A. Mitra, *Green Chem.*, 2012, **14**, 1589–1592.
- 55 N. Yasukawa, Y. Miki, M. Kuwata, H. Sajiki and Y. Sawama, *ChemSusChem*, 2020, **13**, 5632–5637.
- 56 C. M. Zall, J. C. Linehan and A. M. Appel, *J. Am. Chem. Soc.*, 2016, **138**, 9968–9977.
- 57 K. Motokura, D. Kashiwame, N. Takahashi, A. Miyaji and T. Baba, *Chem.–Eur. J.*, 2013, **19**, 10030–10037.
- 58 F. J. Fernández-Alvarez and L. A. Oro, *ChemCatChem*, 2018, **10**, 4783–4796.
- 59 C. Deutsch, N. Krause and B. H. Lipschutz, *Chem. Rev.*, 2008, **108**, 2916–2927.
- 60 A. J. Jordan, G. Lalic and J. P. Sadighi, *Chem. Rev.*, 2016, **116**, 8318–8372.

